MuscleOnGLPHome/Research/August 11-17, 2026
Weekly research roundup
GLP-1 and muscle research: August 11-17, 2026
This week's papers span sarcopenia guidelines, a muscle-sparing drug safety study, a preclinical ketone-ester intervention, and protein metabolism research — all with varying degrees of relevance to people managing muscle loss on GLP-1 medications. Two animal/preprint studies are included for transparency but should be interpreted cautiously. No clinical recommendations are implied by any summary below.
How to read this
- This roundup is compiled automatically from the abstracts of newly published research and is a neutral summary, not medical advice, not peer review, and not an endorsement. Studies vary in quality and preprints are not yet peer-reviewed. Read the linked source and talk to your clinician before changing anything.
Identification and management of sarcopenia in patients with multimorbidity: An EFIM critically appraised and adapted guideline.
The European Federation of Internal Medicine (EFIM) adapted existing sarcopenia clinical practice guidelines specifically for adults with multiple chronic conditions (multimorbidity). Across 37 recommendations, the guideline emphasizes proactive case-finding in adults 65 and older (and in younger adults with specific risk factors), prioritizes muscle strength testing — such as handgrip or chair-stand — as the entry point for assessment, and calls for individualized physical activity and nutritional interventions. Notably, GLP-1/GIP receptor agonists are explicitly listed among treatments that may pose iatrogenic (treatment-induced) risks for muscle loss in this population. Evidence quality across the recommendations ranged from high to low, with some based on expert consensus.
Why it matters: This is a formal multinational clinical guideline that names GLP-1/GIP agonists as a specific sarcopenia risk factor in multimorbid patients and provides a structured framework for screening and managing that risk.
What this means for you: This guideline adds to the case for routinely monitoring muscle strength — such as grip strength or chair-stand performance — particularly for people on GLP-1 medications who also carry multiple chronic conditions.
Semaglutide-induced loss of skeletal muscle mass is blunted by co-administration of ketone esters.
This is a preclinical (mouse) study investigating whether oral ketone ester supplementation could prevent muscle loss caused by semaglutide. In obese, glucose-intolerant mice treated for three weeks, semaglutide alone reduced lean mass, impaired muscle strength, and suppressed mitochondrial gene expression while elevating markers of muscle atrophy. Adding a ketone ester (which generates beta-hydroxybutyrate) preserved muscle mass and function without reducing fat loss, and reversed the semaglutide-associated changes in mitochondrial and atrophy-related gene expression. The authors propose that impaired mitochondrial function and ketone metabolism contribute to GLP-1-induced muscle loss, and call for clinical trials to test whether these findings translate to humans.
Why it matters: This mouse study directly investigates a potential mechanism for — and a nutritional intervention against — semaglutide-induced skeletal muscle loss, a central concern for people on GLP-1 medications, though human translation remains unestablished.
What this means for you: Because this is an animal study, human applicability is unknown; discussing emerging research on muscle-sparing strategies with a clinician is a reasonable next step before drawing conclusions.
Cardiac safety of chronic inhibition of the myostatin-activin pathway with bimagrumab in healthy older adults.
This randomized, double-blind, placebo-controlled trial in 68 healthy adults aged 60–86 tested six months of intravenous bimagrumab (a myostatin-activin pathway inhibitor) at 10 mg/kg versus placebo. Bimagrumab produced a 5.5% increase in total lean body mass and a 14% decrease in fat mass compared with placebo (both statistically significant), with no clinically meaningful change in left ventricular mass index or ejection fraction — the primary cardiac safety endpoints. The authors conclude that six months of myostatin-activin inhibition did not adversely affect cardiac structure or function in this population, and suggest bimagrumab warrants consideration as a muscle-sparing intervention alongside GLP-1 receptor agonists.
Why it matters: This is the first randomized controlled trial to directly assess cardiac safety of bimagrumab — a drug being actively studied in combination with semaglutide — while also demonstrating significant lean mass gain and fat loss, making it highly relevant to the muscle-preservation question on GLP-1 therapy.
What this means for you: Worth discussing with a clinician, as this trial provides cardiac safety and body composition data relevant to the ongoing investigation of bimagrumab as a potential muscle-sparing add-on to GLP-1 medications.
High animal protein and high plant protein meals differentially alter postprandial plasma amino acid concentrations but not glucose homeostasis in people with overweight/obesity in a randomized, cross-over, single-meal study.
This randomized crossover study in adults with overweight or obesity compared a standard-protein meal (~18 g protein) to high-protein meals (~28 g protein) from either animal or plant sources. Both high-protein meals lowered postprandial blood glucose and raised glucagon, GLP-1, and insulin relative to glucose compared with the standard meal, with no significant difference between animal and plant protein on these hormonal measures. However, animal protein produced greater rises in essential and branched-chain amino acids than plant protein, while total amino acid responses were similar. The authors conclude that protein amount — not source — drives postprandial glucoregulatory hormone responses.
Why it matters: The finding that both animal and plant protein sources similarly stimulate GLP-1 and improve postprandial glucose control, while differing in amino acid profiles, is directly relevant to protein food choices for people seeking to optimize both muscle substrate and metabolic response during GLP-1-assisted weight loss.
What this means for you: This is one more reason to discuss overall daily protein targets — and the trade-offs between animal and plant sources — as part of a nutrition plan during GLP-1-assisted weight loss.
Imaging-Derived Sarcopenic Obesity and Cardiovascular Outcomes: Insights Into Heart Failure Risk and Muscle Biology.
Using deep learning applied to over 55,000 cardiac MRI scans, researchers developed a sarcopenic obesity index combining pectoralis major muscle mass with body weight. A higher index was associated with adverse cardiac remodeling and significantly increased risks of incident heart failure, cardiovascular death, and all-cause mortality in multivariable models. Genome-wide analysis identified 16 genetic loci linked to the index, including genes associated with heart failure; transcriptomic profiling showed these loci were specifically activated during muscle atrophy. The authors note that one identified target, ACVR2B, is the target of bimagrumab, which is being studied alongside semaglutide to preserve lean mass during fat loss.
Why it matters: This large imaging study establishes sarcopenic obesity as a measurable cardiovascular risk phenotype and explicitly connects its genetic underpinnings to the semaglutide-plus-bimagrumab research context, underscoring why preserving muscle during GLP-1-driven weight loss may have consequences beyond physical function.
What this means for you: Worth discussing with a clinician how body composition — not just weight or BMI — might factor into cardiovascular risk monitoring during GLP-1-assisted weight loss.
Turn the evidence into a plan
The MuscleOnGLP handbook
These studies point the same direction our guides already put into practice: resistance training and enough protein preserve muscle while you lose weight. The 30-page handbook is the full, cited protocol.
See the handbook — $5 →